Rockville, United States
Sensei Bio, founded in 1999, is a pioneering player in the Biotechnology and Life Sciences sectors, focused on developing cutting-edge immuno-oncology therapies. Their compelling slogan, "We follow the immune system’s teachings to discover new treatments that inspire the body to fight cancer," succinctly captures their mission.
With headquarters in the United States, Sensei Bio has developed the TMAb™ platform, which enhances the body's immune response by targeting the tumor microenvironment. Their strategic focus on leveraging immunology insights to effectively treat cancer as an infection positions them uniquely within the industry.
Their last funding round was a $30.00M Series B, dated January 11, 2021, with participation from prestigious investors like Future Ventures, Pura Vida Investments, Apeiron Investment Group, among others. This investment underscores the strong confidence in Sensei Bio's potential to revolutionize cancer treatment through innovative therapeutic platforms.
